Neutrophil activation and resistance to recombinant human erythropoietin therapy in hemodialysis patients

American Journal of Nephrology

Volumn 28, Issue 6, 2008, Pages 935-940

  Costa, Elísio ^a,b,c   Rocha, Susana ^a,b   Rocha Pereira, Petronila ^b,d   Nascimento, Henrique ^a,b   Castro, Elisabeth ^a,b   Miranda, Vasco ^e   Do Sameiro Faria, Maria ^e   Loureiro, Alfredo ^f   Quintanilha, Alexandre ^a,b   Belo, Luís ^a,b   Santos Silva, Alice ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c CBQF CENTRO DE BIOTECNOLOGIA E QUÍMICA FINA LABORATÓRIO ASSOCIADO   (Portugal)

^d UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^e FRESENIUS MEDICAL CARE PORTUGAL   (Portugal)

^f Uninefro Santo Tirso Sociedade Prestadora de Cuidados Medicos e Dialise SA   (Portugal)

Author keywords

Elastase; Lactoferrin; Neutrophil activation; rhEPO therapy, resistance

Indexed keywords

C REACTIVE PROTEIN; ELASTASE; HEMOGLOBIN; LACTOFERRIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG RESPONSE; ENZYME BLOOD LEVEL; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; LEUKOCYTE ACTIVATION; LEUKOCYTE DIFFERENTIAL COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PRIORITY JOURNAL;

EID: 53549130236     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000142147     Document Type: Article

References (18)

1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 1998;32(suppl 3):S112-S119.
2. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy morbidity and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61.
3. Locatelli F, Conte F, Marcelli D: The impact of hematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - the experience of the Lombardy dialysis registry. Nephrol Dial Transplant 1998;13:1642-1644.
4. Spittle MA, Hoenich NA, Handelman GJ, Adhikarla R, Homel P, Levin NW: Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 2001;38:1408-1413.
5. Pupim LB, Himmelfarb J, McMonagle E, Shyr Y, Ikizler TA: Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int 2004;65:2371-2379.
6. Sommerburg O, Grune T, Hampl H, Riedel E, van Kuijk FJ, Ehrich JHH, Siems WG: Does long-term treatment of renal anemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients? Nephrol Dial Transplant 1998;13:2583-2587.
7. Lucchi L, Bergamini S, Botti B, Rapanà R, Ciuffreda A, Ruggiero P, Ballestri M, Tomasi A, Albertazzi A: Influence of different hemodialysis membranes on red blood cell susceptibility to oxidative stress. Artif Organs 2000;24:1-6.
8. Valentini J, Schmitt GC, Grotto D, Santa Maria LD, Boeira SP, Piva SJ, Brucker N, Bohrer D, Pomblum VJ, Emanuelli T, Garcia SC: Human erythrocyte delta-aminolevulinate dehydratase activity and oxidative stress in hemodialysis patients. Clin Biochem 2007;40:591-594.
9. Skoutelis AT, Kaleridis VE, Goumenos DS, Athanassiou GM, Missirlis YF, Vlachojannis JG, Bassaris HP: Polymorphonuclear leukocyte rigidity is defective in patients with chronic renal failure. Nephrol Dial Transplant 2000;15:1788-1793.
10. Leitienne P, Fouque D, Rigal D, Adeleine P, Trzeciak MC, Laville M: Heparins and blood polymorphonuclear stimulation in haemodialysis: an expansion of the biocompatibility concept. Nephrol Dial Transplant 2000;15:1631-1637.
11. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S; European Best Practice Guidelines Working Group: Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(suppl 2):ii1-ii47.
12. Bárány P: Inflammation, serum C-reactive protein, and erythropoietin resistance. Nephrol Dial Transplant 2001;16:224-227.
13. Costa E, Lima M, Alves JM, Rocha S, Rocha-Pereira P, Castro E, Miranda V, Sameiro-Faria M, Loureiro A, Quintanilha A, Belo L, Santos-Silva A: Inflammation, T-cell phenotype and inflammatory cytokines in chronic kidney disease patients under haemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. J Clin Immunol 2008;28:268-275.
14. Belo L, Santos-Silva A, Caslake M, Cooney J, Pereira-Leite L, Quintanilha A, Rebelo I: Neutrophil activation and C-reactive protein concentration in preeclampsia. Hypertens Pregnancy 2003;22:129-141.
15. Levay PF, Viljoen M: Lactoferrin: a general review. Haematologica 1995;80:252-267.
16. Costa E, Pereira BJG, Rocha-Pereira P, Rocha S, Reis F, Castro E, Teixeira F, Miranda V, Sameiro Faria M, Loureiro A, Quintanilha A, Belo L, Santos-Silva A: Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. Am J Nephrol 2008;28:677-683.
17. Dasselaar JJ, Hooge MNL, Pruim J, Nijnuis H, Wiersum A, Jong PE, Huisman RM, Franssen CFM: Relative blood volume changes underestimated total blood volume changes during hemodialysis. Clin J Am Soc Nephrol 2007;2:669-674.
18. Yu AW, Nawab ZM, Barnes WE, Lai KN, Ing TS, Daugirdas JT: Splanchnic erythrocyte content decreases during hemodialysis: a new compensatory mechanism for hypovolemia. Kidney Int 1997;51:1986-1990.